logo

RXRX’s Financial Health: Exploring Recursion Pharmaceuticals Inc’s Debt-to-Equity Ratio of 1.79

Recursion Pharmaceuticals Inc’s stock market performance has been somewhat irregular. The 1-year high for the company’s stock was recorded at $15.74 on 02/27/24, with the lowest value being $5.60 on 11/22/24.

52-week price history of RXRX Stock

Analyzing the 52-week price history of a stock, including its high and low prices, can provide valuable insight into its current status and potential future performance. Recursion Pharmaceuticals Inc’s current trading price is -56.48% away from its 52-week high, while its distance from the 52-week low is 22.32%. The stock’s price range for this period has remained between $5.60 and $15.74. The Healthcare sector company’s shares managed to surpass a trading volume of around 9.21 million for the day, which was noticeably higher compared to the shares’ average daily volume of 6.03 million over the last three months.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Financial Performance and Market Capitalization

Recursion Pharmaceuticals Inc (RXRX) has experienced a quarterly decline of -5.91% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.66B.

Moving average and trading volume data

Based on Barchart.com data, the company’s moving average over the 100-day period was 6.88, with a change in price of -0.34. Similarly, Recursion Pharmaceuticals Inc recorded 5,774,169 in trading volume during the last 100 days, posting a change of -4.70%.

RXRX Debt-to-equity ratio analysis

The debt-to-equity (D/E) ratio is a valuable metric that offers insight into a company’s financial health and standing in the market. This ratio is calculated by dividing a company’s current total liabilities by its shareholders’ equity. The D/E ratio illustrates the extent of debt a company is utilizing to support its assets in relation to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for RXRX stands at 0.17. Similarly, the long-term debt-to-equity ratio is also 0.14.

RXRX Stock Stochastic Average

As of today, the raw stochastic average of Recursion Pharmaceuticals Inc over the past 50 days is 44.64%. This is a increase compared to the raw stochastic average of the last 20 days, which was recorded at 44.64%. Additionally, the Stochastic %K and %D values for the company were 32.87% and 23.72%, respectively, over the past 20 days.

RXRX Stock Price Performance Analysis

The stock price performance over the year has been a mixed bag, resulting in a range of outlooks from optimistic to pessimistic depending on the observer. Year to date metric has recorded a loss of -30.53%.However, over the last six months, we can see a stronger performance of -17.27%. Over the last 30 days, the price of RXRX has fallen by 2.54%. And in the last five days, it has surged by 19.13%.

Most Popular